Clozapine-induced weight gain: prevalence and clinical relevance
1992; American Psychiatric Association; Volume: 149; Issue: 1 Linguagem: Inglês
10.1176/ajp.149.1.68
ISSN1535-7228
AutoresR. Leadbetter, Michael S. Shutty, Diane Pavalonis, Victor Vieweg, Patricia Grant Higgins, Murna Downs,
Tópico(s)Mental Health and Psychiatry
ResumoBack to table of contents Previous article Next article No AccessClozapine-induced weight gain: prevalence and clinical relevancePublished Online:1 Apr 2006https://doi.org/10.1176/ajp.149.1.68AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractOBJECTIVE: The aim of this study was to determine the prevalence and clinical relevance of weight gain during clozapine treatment. Previous reports indicated clinically significant weight gain in 13% to 85% of patients and an average gain of 9.0 to 24.7 lb. METHOD: Twenty-one state hospital patients with treatment-resistant schizophrenia or schizoaffective disorder were weighed weekly for 12 weeks before clozapine treatment and during the first 16 weeks of treatment. Psychiatric symptoms were rated with a modified version of the Brief Psychiatric Rating Scale (BPRS). RESULTS: The mean weight gain for the entire group was 13.9 lb, or 8.9% of body weight. During the 16 weeks of clozapine treatment, 38% of the patients experienced marked weight gains and 29% had moderate weight gains. The improvements in BPRS total score and composite negative symptom score were significantly greater for the eight patients with marked weight gains than for the other 13 patients. CONCLUSIONS: Clozapine's propensity to induce weight gain may relate to the drug's efficacy and/or its unique neuropharmacologic effects. Increased attention to this phenomenon is important because of the morbidity associated with obesity. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byEffect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)31 January 2023 | BMJ Open, Vol. 13, No. 1Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophreniaAsian Journal of Psychiatry, Vol. 74Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment28 October 2021 | Journal of Clinical Psychopharmacology, Vol. 42, No. 1Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat SchizophreniaJournal of Child and Adolescent Psychopharmacology, Vol. 31, No. 10Assessment of metabolic risk factors in patients undergoing antipsychotic drug therapy: A Pharmacist-led studyLe Pharmacien Hospitalier et Clinicien, Vol. 1Sex-specific Association of Antipsychotic-induced Weight Gain and Treatment Response for Antipsychotic-Naive First Episode Schizophrenia Patients: A Prospective 8-week Longitudinal Study24 February 2021 | Pharmacopsychiatry, Vol. 54, No. 02Recent findings leading to the discovery of selective dopamine D4 receptor ligands for the treatment of widespread diseasesEuropean Journal of Medicinal Chemistry, Vol. 212The side effect profile of Clozapine in real world data of three large mental health hospitals8 December 2020 | PLOS ONE, Vol. 15, No. 12Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia4 December 2020 | Scientific Reports, Vol. 10, No. 1Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox3 November 2020 | Frontiers in Psychiatry, Vol. 11Underlying Susceptibility to Eating Disorders and Drug Abuse: Genetic and Pharmacological Aspects of Dopamine D4 Receptors30 July 2020 | Nutrients, Vol. 12, No. 8Clozapine reliably increases the motivation for food: parsing the role of the 5-HT2c and H1 receptors3 January 2020 | Psychopharmacology, Vol. 237, No. 4Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale6 June 2018 | Angiology, Vol. 70, No. 2Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosisSchizophrenia Research, Vol. 197Frontiers in Neuroscience, Vol. 11Frontiers in Neuroscience, Vol. 11Psychopharmacology, Vol. 233, No. 14European Neuropsychopharmacology, Vol. 26, No. 2Medical management of patients on clozapine: A guide for internists23 March 2015 | Journal of Hospital Medicine, Vol. 10, No. 8European Journal of Clinical Pharmacology, Vol. 71, No. 4European Neuropsychopharmacology, Vol. 25, No. 1Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophreniaPsychiatric Genetics, Vol. 24, No. 6TreatmentClozapineAdministration of Clozapine and Excessive Elevated Serum TriglyceridesJournal of Clinical Psychopharmacology, Vol. 34, No. 3Asian Journal of Psychiatry, Vol. 8Asian Journal of Psychiatry, Vol. 11Pathology - Research and Practice, Vol. 210, No. 1British Journal of Psychiatry, Vol. 204, No. 2Eating-Behavior Changes Associated With Antipsychotic Medications in Patients With Schizophrenia as Measured by the Drug-Related Eating Behavior QuestionnaireJournal of Clinical Psychopharmacology, Vol. 33, No. 1Brain Research, Vol. 1508Journal of Child and Adolescent Psychopharmacology, Vol. 23, No. 8Clinical Schizophrenia & Related Psychoses, Vol. 6, No. 4Clinical Psychopharmacology and Neuroscience, Vol. 11, No. 1, Vol. 212Molecular Diagnosis & Therapy, Vol. 16, No. 2Asian Journal of Psychiatry, Vol. 5, No. 4Clinical Schizophrenia & Related Psychoses, Vol. 6, No. 3Clinical Psychopharmacology and Neuroscience, Vol. 10, No. 1NeuroMolecular Medicine, Vol. 13, No. 4Progress in Neurobiology, Vol. 95, No. 2Clinical Pharmacology & Therapeutics, Vol. 90, No. 1A Longitudinal Study on the Impact of Antipsychotic Treatment on Serum Leptin in SchizophreniaClinical Neuropharmacology, Vol. 33, No. 6Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatmentPharmacogenetics and Genomics, Vol. 20, No. 6Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, Vol. 15, No. 3European Neuropsychopharmacology, Vol. 20, No. 8Psychiatry Research, Vol. 176, No. 2-3Psychiatry Research, Vol. 177, No. 3Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medicationsPrimary Care Diabetes, Vol. 3, No. 1DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain11 March 2008 | The Pharmacogenomics Journal, Vol. 9, No. 1Acta Neurologica Scandinavica, Vol. 89, No. 4Acta Psychiatrica Scandinavica, Vol. 120, No. 6Journal of Neural Transmission, Vol. 115, No. 11Physiology & Behavior, Vol. 95, No. 1-2Journal of Korean Academy of Nursing, Vol. 38, No. 4No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation19 September 2006 | The Pharmacogenomics Journal, Vol. 7, No. 4Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients2 January 2007 | Molecular Psychiatry, Vol. 12, No. 5Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden27 February 2007 | Proceedings of the National Academy of Sciences, Vol. 104, No. 9Journal of Neural Transmission, Vol. 114, No. 2Journal of Neural Transmission, Vol. 114, No. 8Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 31, No. 2Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 31, No. 6Schizophrenia Research, Vol. 91, No. 1-3Journal of Clinical Psychopharmacology, Vol. 27, No. 1Clozapine enhances differentiation of adipocyte progenitor cells25 October 2006 | Molecular Psychiatry, Vol. 11, No. 11Genetics of antipsychotic treatment emergent weight gain in schizophreniaPharmacogenomics, Vol. 7, No. 6Association of Initial Antipsychotic Response to Clozapine and Long-Term Weight GainYa Mei Bai, M.D.Chao-Cheng LinJen-Yeu ChenChih-Yuan Lin, M.D.Tung-Ping Su, M.D.Pesus Chou, Ph.D.1 July 2006 | American Journal of Psychiatry, Vol. 163, No. 7Risperidone-related Weight GainJournal of Clinical Psychopharmacology, Vol. 26, No. 2Journal de Thérapie Comportementale et Cognitive, Vol. 16, No. 2Child and Adolescent Psychiatric Clinics of North America, Vol. 15, No. 1Schizophrenia Research, Vol. 86, No. 1-3CNS Drug Reviews, Vol. 5, No. 3Jornal Brasileiro de Psiquiatria, Vol. 55, No. 4C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese populationPharmacogenetics and Genomics, Vol. 15, No. 10Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related DisordersJournal of Clinical Psychopharmacology, Vol. 25, No. 3Prise de poids et antipsychotiques : investigation et traitement de la restriction cognitive. Étude préliminaireJournal de Thérapie Comportementale et Cognitive, Vol. 15, No. 1American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, Vol. 133B, No. 1Journal of Neural Transmission, Vol. 112, No. 10, Vol. 65CNS Spectrums, Vol. 10, No. S2Annals of Clinical Psychiatry, Vol. 17, No. 2Drug Development and Industrial Pharmacy, Vol. 31, No. 4-5Clinical and Experimental Pharmacology and Physiology, Vol. 32, No. 4BMC Psychiatry, Vol. 5, No. 1CNS Drugs, Vol. 19, No. Supplement 1Pharmacogenetics of Psychotropic Drug ResponseAnil K. Malhotra, M.D., Greer M. MurphyJr., M.D., Ph.D., and James L. Kennedy, M.D.1 May 2004 | American Journal of Psychiatry, Vol. 161, No. 5Therapeutic Options in the Treatment of Clozapine-Induced Adverse Effects3 August 2016 | Journal of Pharmacy Technology, Vol. 20, No. 3Current Diabetes Reports, Vol. 4, No. 1Medical Hypotheses, Vol. 62, No. 3Schizophrenia Research, Vol. 70, No. 1Psychiatry and Clinical Neurosciences, Vol. 58, No. 4Behavioural management of antipsychotic-induced weight gain: a review2 September 2003 | Acta Psychiatrica Scandinavica, Vol. 108, No. 4Weight Gain in First-Episode Psychosis1 May 2003 | The Canadian Journal of Psychiatry, Vol. 48, No. 4Clinical Therapeutics, Vol. 25, No. 4Psychiatric Clinics of North America, Vol. 26, No. 1Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, No. 5Psychoneuroendocrinology, Vol. 28Schizophrenia Research, Vol. 59, No. 1Schizophrenia Research, Vol. 62, No. 1-2Journal of the American Medical Directors Association, Vol. 4, No. 4Clinical Neuroscience Research, Vol. 3, No. 1-2Journal of Clinical Psychopharmacology, Vol. 23, No. 3Expert Review of Neurotherapeutics, Vol. 3, No. 1Current Diabetes Reports, Vol. 2, No. 2Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 26, No. 2Clinical and Experimental Pharmacology and Physiology, Vol. 29, No. 11Journal of Clinical Psychopharmacology, Vol. 22, No. 3Journal of Clinical Psychopharmacology, Vol. 22, No. 3International Clinical Psychopharmacology, Vol. 17, No. 4Psychiatric Genetics, Vol. 12, No. 3Euglycemic Clamp Study in Clozapine-Induced Diabetic Ketoacidosis28 June 2016 | Annals of Pharmacotherapy, Vol. 35, No. 11Plasma Protein and Lipoprotein Distribution of ClozapineRic M. Procyshyn, Ph.D., Nathan B. Kennedy, Samantha Marriage, and Kishor M. Wasan, Ph.D.1 June 2001 | American Journal of Psychiatry, Vol. 158, No. 6Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities1 April 2001 | The Canadian Journal of Psychiatry, Vol. 46, No. 3International Journal of Geriatric Psychiatry, Vol. 16, No. S1Brain Research, Vol. 923, No. 1-2Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 25, No. 8Schizophrenia Research, Vol. 49, No. 3International Clinical Psychopharmacology, Vol. 16, No. 3Pharmacogenetics, Vol. 11, No. 3Drug Safety, Vol. 24, No. 1CNS Drugs, Vol. 15, No. 7Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic StudyDavid C. Henderson, M.D., Enrico Cagliero, M.D., Colin Gray, Rima A. Nasrallah, B.S., Doug L. Hayden, M.A., David A. Schoenfeld, Ph.D., and Donald C. Goff, M.D.1 June 2000 | American Journal of Psychiatry, Vol. 157, No. 6General Hospital Psychiatry, Vol. 22, No. 4Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment28 January 2000 | Molecular Psychiatry, Vol. 5, No. 1Psychiatry and Clinical Neurosciences, Vol. 54, No. 4Journal of Psychiatric Practice, Vol. 6, No. 6Expert Opinion on Pharmacotherapy, Vol. 1, No. 3Effects of Psychotropic Drugs on WeightPsychiatric Annals, Vol. 29, No. 10New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Olanzapine TreatmentPsychosomatics, Vol. 40, No. 5The Schizophrenia AlgorithmLeo H. Berman, M.D.1 May 1999 | Psychiatric Services, Vol. 50, No. 5Weight Gain Among Patients on ClozapineYa-Mei Bai, M.D., Chao-Cheng Lin, M.D., Jen-Yeu Chen, M.D., and Chih-Yuan Lin, M.D.1 May 1999 | Psychiatric Services, Vol. 50, No. 5Efectividad de la clozapina en un servicio psiquiátrico en Italia12 May 2020 | European psychiatry (Ed. Española), Vol. 6, No. 2Journal of Clinical Psychopharmacology, Vol. 19, No. 3Journal of Clinical Psychopharmacology, Vol. 19, No. 4Acta Psychiatrica Scandinavica, Vol. 100, No. 1Pharmacotherapy, Vol. 19, No. 9Weight Changes during Clozapine Treatment26 June 2016 | Australian & New Zealand Journal of Psychiatry, Vol. 32, No. 5Clozapine effectiveness in a psychiatric service in Italy16 April 2020 | European Psychiatry, Vol. 13, No. 6Biological Psychiatry, Vol. 43, No. 7Biological Psychiatry, Vol. 44, No. 8Biological Psychiatry, Vol. 44, No. 5Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial1 April 2006 | American Journal of Psychiatry, Vol. 154, No. 4Drug Development Research, Vol. 41, No. 1Predictors of Response to ClozapinePsychiatric Annals, Vol. 26, No. 7Differential effect of clozapine on weight: a controlled study1 April 2006 | American Journal of Psychiatry, Vol. 153, No. 6European Neuropsychopharmacology, Vol. 6European Journal of Pharmacology, Vol. 317, No. 2-3Clozapine Therapy in Patients with Neurologic Illness1 January 1996 | The International Journal of Psychiatry in Medicine, Vol. 25, No. 4Family experience with positive client response to clozapineArchives of Psychiatric Nursing, Vol. 9, No. 1Human Psychopharmacology: Clinical and Experimental, Vol. 10, No. 5European Neuropsychopharmacology, Vol. 5, No. 4, Vol. 18Journal of the American College of Nutrition, Vol. 13, No. 2Journal of the American Academy of Child & Adolescent Psychiatry, Vol. 33, No. 5Atypicality of clozapine26 June 2016 | Annals of Pharmacotherapy, Vol. 27, No. 12Pharmacology & Therapeutics, Vol. 57, No. 1Clozapine in the Treatment of Refractory Schizophrenia: Canadian Policies and Clinical Guidelines *1 September 1992 | The Canadian Journal of Psychiatry, Vol. 37, No. 7La clozapine dans le traitement de la schizophrénie réfractaire: règles et directives canadiennes *1 September 1992 | The Canadian Journal of Psychiatry, Vol. 37, No. 7Weight gain among schizophrenic patients treated with clozapine1 April 2006 | American Journal of Psychiatry, Vol. 149, No. 5 Volume 149Issue 1 January 1992Pages 68-72 Metrics PDF download History Published online 1 April 2006 Published in print 1 January 1992
Referência(s)